Candel Therapeutics, Inc. 8-K

What Happened

• On February 19, 2026, Candel Therapeutics, Inc. announced a Purchase Agreement with funds managed by RTW Investments, LP under which the purchaser will pay the company $100 million upon U.S. FDA approval of CAN-2409 (aglatimagene besadenovec) for intermediate‑risk and high‑risk localized prostate cancer.
• In exchange, the purchaser receives a tiered royalty on U.S. net sales of the Product, with payments starting after the first commercial sale and ending when the purchaser has received $250 million in royalties. The Company also furnished a press release (Exhibit 99.1) and reported preliminary cash of approximately $119.7 million as of December 31, 2025 (unaudited).

Key Details

• Purchase price: $100.0 million payable upon FDA approval for the specified prostate cancer indication.
• Royalty structure: 4.67% on annual U.S. net sales ≤ $1 billion; 1.33% on portion > $1 billion. The 4.67% tier can increase to 6.67% (a “Ratchet”) if sales do not meet specified thresholds, with a company cure opportunity.
• Royalty cap and termination: Royalties cease once the purchaser has received $250 million. The agreement includes a Buy‑Out Option allowing payment of specified amounts (depending on timing) to terminate the agreement up to the Royalty Cap.
• Conditions: Transaction is subject to closing conditions, including that FDA approval occur by a specified date and certain indebtedness and customary closing requirements.

Why It Matters

• This is contingent, non‑dilutive financing tied to regulatory success: Candel would receive $100M only if CAN‑2409 obtains the specified FDA approval. It shifts a portion of future U.S. product revenue to the purchaser in exchange for upfront capital upon approval.
• The royalty cap ($250M) and ratchet feature affect how much long‑term revenue the company retains versus pays out, important for investors modeling future revenue and valuation.
• The company’s preliminary cash balance (~$119.7M, unaudited) provides context on current liquidity but may change when audited year‑end results are finalized.
• Closing depends on FDA approval and other conditions, so investors should treat the $100M as conditional and watch for regulatory and closing updates.